Larimar Therapeutics Inc.

2.00
-0.20 (-9.09%)
At close: Apr 03, 2025, 2:01 PM

Company Description

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform.

Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease.

The company is based in Bala Cynwyd, Pennsylvania.

Larimar Therapeutics Inc.
Larimar Therapeutics Inc. logo
Country United States
IPO Date Jun 19, 2014
Industry Biotechnology
Sector Healthcare
Employees 65
CEO Dr. Carole S. Ben-Maimon M.D.

Contact Details

Address:
Three Bala Plaza East
Bala Cynwyd, Pennsylvania
United States
Website https://www.larimartx.com

Stock Details

Ticker Symbol LRMR
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001374690
CUSIP Number 517125100
ISIN Number US5171251003
Employer ID 20-3857670
SIC Code 2834

Key Executives

Name Position
Dr. Carole S. Ben-Maimon M.D. Chief Executive Officer, President & Director
Michael Celano CPA Secretary & Chief Financial Officer
Dr. Gopi Shankar M.B.A., Ph.D. Chief Development Officer
Dr. Russell G. Clayton Sr., D.O, D.O. Chief Medical Officer
Francis Michael Conway CPA Vice President & Controller
Jennifer Spokes Johansson Vice President of Legal & Compliance
John Berman Vice President of Finance & Administration

Latest SEC Filings

Date Type Title
Mar 24, 2025 S-8 Filing
Mar 24, 2025 10-K Annual Report
Mar 24, 2025 8-K Current Report
Feb 04, 2025 SCHEDULE 13G Filing
Jan 27, 2025 8-K Current Report
Jan 24, 2025 4 Filing
Jan 24, 2025 4 Filing
Jan 24, 2025 4 Filing
Jan 24, 2025 4 Filing
Jan 10, 2025 8-K Current Report